DAIICHI SANKYO COMPANY, LIMITED (4568) Stock Price

Daiichi Sankyo is a pharmaceutical company group whose primary business is the manufacturing and sale of pharmaceutical products. The group consists of Daiichi Sankyo and 48 subsidiary companies, along with 2 affiliated companies. Daiichi Sankyo conducts research and development, manufacturing, and sales of pharmaceutical products, with operations spanning both domestic and international markets.

Domestically, Daiichi Sankyo Pharma and Daiichi Sankyo Chemical Pharma handle pharmaceutical manufacturing. Daiichi Sankyo Healthcare conducts research, development, and sales of over-the-counter medicines, while Daiichi Sankyo Biotech manages vaccine research, development, and manufacturing. These subsidiaries supply products to Daiichi Sankyo.

Internationally, in the United States, Daiichi Sankyo Inc. conducts pharmaceutical research, development, and sales under Daiichi Sankyo U.S. Holdings. In Europe, Daiichi Sankyo Europe GmbH and its group companies handle pharmaceutical research, development, manufacturing, and sales. In other regions, the company conducts pharmaceutical research, development, manufacturing, and sales in markets including China and Brazil.

Daiichi Sankyo Business Associates provides administrative services such as human resources and accounting to Daiichi Sankyo and domestic group companies, and also handles real estate leasing and insurance agency operations. These services enhance operational efficiency across the entire group.

Daiichi Sankyo aims to enhance both financial and non-financial value based on ESG management. The company positions "Science & Technology" as a source of competitive advantage and seeks to achieve sustainable growth by delivering value to society and stakeholders.

As its 2030 Vision, Daiichi Sankyo has established the goal of becoming "an innovative global healthcare company contributing to the development of a sustainable society." To realize this vision, the company aims to improve the health and quality of life for people worldwide through the creation of innovative pharmaceuticals and initiatives aligned with the SDGs.

Under the Fifth Medium-Term Management Plan (fiscal 2021–2025), Daiichi Sankyo is pursuing ESG management practices while working to become "an innovative global drug discovery company with strengths in oncology" by fiscal 2025. This plan includes maximizing 3ADCs, driving profit growth in existing businesses, building new growth pillars, and co-creating value with stakeholders.

Daiichi Sankyo prioritizes maximizing 3ADCs (Enhertu, Dato-DXd, and HER3-DXd) and is accelerating market penetration through a partnership with AstraZeneca. The company is establishing competitive advantages against rival products targeting HER2 and TROP2, aiming to establish new treatment concepts in cancer therapy.

The company also emphasizes profit growth in existing businesses by expanding sales of new products such as Lixiana, Talige, and Nilotinib. This approach supports sustained growth in non-oncology pharmaceutical businesses while expanding sales of high-margin products.

Additionally, Daiichi Sankyo is advancing a multimodality research strategy to identify growth drivers beyond 3ADCs. The company is progressing with post-DXd ADC modality selection, including vaccine business growth through LNP-mRNA technology.

Value co-creation with stakeholders is also a priority. The company is strengthening patient-centric mindsets and addressing social and environmental challenges through renewable energy adoption and vaccine supply infrastructure development.

Daiichi Sankyo is advancing digital transformation to realize data-driven management. The company is strengthening its global management structure to enable rapid decision-making and support strategy execution.

Regarding shareholder returns, Daiichi Sankyo implements dividend increases and share buybacks in line with profit growth, aiming to maximize shareholder value. The company has set a target dividend on equity (DOE) of 8% or higher by fiscal 2025.